Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers

• ClinicalTrials.gov Identifier: NCT06035536
• Recruitment Status: Recruiting
• First Posted: September 13, 2023
• Last Update Posted: November 22, 2023
• Sponsor: Aroa Biosurgery Limited
• Collaborator: Professional Education and Research Institute
• Information provided by (Responsible Party): Aroa Biosurgery Limited

Study Description

Brief Summary:

The study will evaluate the safety and performance of Symphony™ versus Standard of Care (SOC) in the treatment of chronic non-healing diabetic foot ulcers (DFU) after 12 weeks of treatment.

Condition or disease	Intervention/treatment	Phase
Diabetic Foot; Diabetic Foot Ulcer; Foot Ulcer; Chronic Foot Ulcer	Device: Symphony™ plus Off-loading; Device: Wound Dressing comprising of calcium alginate Fibracol	Not Applicable

Detailed Description:

About 120 subjects will take part in this study. Subjects with a Wagner Grade 1 or 2 Diabetic Foot Ulcers will be randomized at a ratio of 1:1 to one of the two treatment groups at the time of completion of screening to either Symphony™ treatment or Standard of Care (SOC) treatment groups.

Following initial enrolment, eligible subjects will then undergo:

• A screening phase consisting of 14 days to determine eligibility.
• Eligible subjects will then undergo a treatment phase involving weekly treatment and evaluations for up to 12 weeks.
• Subjects that heal will undergo a follow-up phase that includes 1 visit (Healing Confirmation Visit), 2 weeks from initial healing.
• If the subject does not heal, they will exit at Week 13, End of Study visit.

Both treatment groups will receive accepted routine procedures being part of SOC, including offloading of the DFU (removable cast boot or total contact casting [TCC] if the subject's foot is too large for a removable cast boot), appropriate sharp or surgical debridement, and infection management.

In addition to what is noted above, Group 1 will receive a weekly application of Symphony™ and Group 2 will receive SOC comprising of calcium alginate Fibracol dressing. Both Groups will have a silicone non-adherent dressing (MepitelTM or equivalent), a padded 3-layer dressing comprised of 4x4 gauze pads, soft roll, compressive wrap and Coban (Threeflex 3layer or equivalent) applied.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 120 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Masking Description: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multi-Center, Randomized Controlled Clinical Investigation Evaluating Wound Closure With Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
• Actual Study Start Date: June 8, 2023
• Estimated Primary Completion Date: December 27, 2024
• Estimated Study Completion Date: December 27, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Symphony™ treatment; Arm receives an application of Symphony™ treatment and appropriate Off-loading.	Device: Symphony™ plus Off-loading; Application of Symphony™
Active Comparator: Standard of Care (SOC) treatment; Arm receives an application of SOC comprising of calcium alginate Fibracol dressing and appropriate Off-loading.	Device: Wound Dressing comprising of calcium alginate Fibracol; Application of Wound Dressing comprising of calcium alginate Fibracol.

Outcome Measures

Primary Outcome Measures :

1. Percentage of index ulcers healed at 12 weeks [ Time Frame: 12 weeks ]
   Percentage of index ulcer defined as 100% re-epithelialization within 12 weeks

Secondary Outcome Measures :

1. Time to heal within 12 weeks [ Time Frame: 12 weeks ]
   Time to heal of index ulcer defined as 100% re-epithelialization within 12 weeks
2. Percentage area reduction at 12 weeks [ Time Frame: 12 weeks ]
   Area reduction percentage of ulcer at 12 weeks
3. Changes in wound quality of life (per W-QoL) [ Time Frame: after 12 weeks ]
   Changes in wound quality of life (W-QoL) using the W-QoL short questionnaire administered on Study Visit 1 (as a baseline) and after 12 weeks of treatment (End of Study Visit) normalized to a single value. Each item is scored on a 5-point Likert scale from 0 (not at all) to 4 (very much).
4. Change in pain levels during the clinical investigation [ Time Frame: 12 weeks ]
   Change in subject-reported pain levels using the 0-10 Numeric Pain Rating Scale at each weekly visit. On the numerical pain scale, the number 0 represents "no pain" and the number 10 represents "the worst possible pain".

Other Outcome Measures:

1. Product wastage (Symphony only) [ Time Frame: 12 weeks ]
   Product wastage (applies only to DFUs treated with Symphony). Area of Symphony device; wound area at time of application based on digital planimetry imaging of area. Percentage wastage: (Area of DFU - area of Symphony/area of DFU) x 100.
2. Cost to closure (both treatment groups; all wounds, and only closed wounds) [ Time Frame: 12 weeks ]
   Costs for all wounds per treatment group, and cost of healed wounds only per treatment group. Final values are cost per wound.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• 1. At least 18 years old, inclusive.
• 2. Presence of a DFU, Wagner Grade 1 or 2 (see Appendix B for definitions), extending through the dermis provided it is below the medial aspect of the malleolus.
• 3. The index ulcer (ulcer to be evaluated in the study) will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer.
• 4. Index ulcer has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study.
• 5. Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1.
• 6. Within 3 months of SV1, adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of > 0.6 is acceptable.
• 7. The target ulcer has been offloaded for at least 14 days, prior to TV1.
• 8. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
• 9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
• 10. Subjects must have read and signed the IRB approved ICF before screening procedures are performed.

Exclusion Criteria:

• 1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes
• 2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer
• 3. Index ulcer is overtly infected (i.e., purulent drainage)
• 4. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study
• 5. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding SV1
• 6. History of radiation at the ulcer site (regardless of time since last radiation treatment)
• 7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies
• 8. Subjects with a previous diagnosis of HIV or Hepatitis C
• 9. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment
• 10. Osteomyelitis or bone infection of the affected foot as verified by xray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision)
• 11. Subject is pregnant or breast-feeding
• 12. Presence of diabetes with poor metabolic control as documented with an HbA1c >12.0 within last 90 days
• 13. Subjects with end stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of enrollment
• 14. Presence of acute Charcot Neuroarthropathy to the affected limb
• 15. Index ulcer that has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit

Contacts and Locations

Contacts

Contact: Shelby Caylor; 513-815-8160; scaylor@periedu.com

Contact: Frances Parker; 540-581-6915; fparker@peredu.com

Locations

United States, California

LA Foot and Ankle; Recruiting

Los Angeles, California, United States, 90010

Contact: Maira Jackson 213-365-0793 maira@lafootpain.com

Principal Investigator: Felix Sigal, DPM

Clemente Clinical Research Inc.; Recruiting

Los Angeles, California, United States, 90033

Contact: Stanley Mathis, DPM 949-412-8445

Bay Area Foot Care; Recruiting

San Francisco, California, United States, 94115

Contact: Maria Peralta 800-363-1069 ext 104 maria@ccr-trials.com

Principal Investigator: Alex Reyzelman, DPM

United States, Florida

Doctor's Research Network; Recruiting

Miami, Florida, United States, 33143

Contact: Patria Division 305-665-3017 pdivison@drnmiami.com

Principal Investigator: Jason Hanft

Barry University Clinical Research; Recruiting

Tamarac, Florida, United States, 33321

Contact: Maria Swartz 305-836-7550 MSwartz@barry.edu

Principal Investigator: Robert Snyder, DPM

United States, North Carolina

Foot and Ankle Specialists of the Mid-Atlantic; Recruiting

Gastonia, North Carolina, United States, 28054

Contact: Dana Jones 704-861-0425 dvandyck@footandankle-usa.com

Principal Investigator: Ryan Meredith, DPM

United States, Ohio

Lower Extremity Institute for Research and Therapy; Recruiting

Boardman, Ohio, United States, 44512

Contact: Jessica DiDomenico 234-719-7588 jessica@leirt.com

Principal Investigator: Lawrence A DiDomenico, DPM

United States, Pennsylvania

Martin Foot and Ankle; Recruiting

York, Pennsylvania, United States, 17402

Contact: Maria Kasper, DPM 717-757-3537 drmariakasper@yahoo.com

Contact: Renee Green 717-757-3537 rgreen@martinfootandankle.com

Principal Investigator: Maria A Kasper, DPM

Sponsors and Collaborators

Aroa Biosurgery Limited

Professional Education and Research Institute

Investigators

• Study Chair: David Armstrong, DPM, MD PhD; Keck School of Medicine

More Information

• Responsible Party: Aroa Biosurgery Limited
• ClinicalTrials.gov Identifier: NCT06035536
• Other Study ID Numbers: AROA 003
• First Posted: September 13, 2023
• Last Update Posted: November 22, 2023
• Last Verified: November 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Aroa Biosurgery Limited:

Extracellular matrix; Regenerative medicine; Leg ulcer; Diabetes Mellitus; Diabetic Angiopathies; Diabetes Complications

Additional relevant MeSH terms:

Diabetic Foot; Foot Ulcer; Ulcer; Pathologic Processes; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Leg Ulcer; Skin Ulcer; Skin Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Diabetic Neuropathies; Foot Diseases; Calcium; Calcium-Regulating Hormones and Agents; Physiological Effects of Drugs